The repurposing of Tebipenem pivoxil as alternative therapy for severe gastrointestinal infections caused by extensively drug-resistant Shigella spp
<strong>Background:<br></strong> Diarrhoea remains one of the leading causes of childhood mortality globally. Recent epidemiological studies conducted in low-middle income countries (LMICs) identified Shigella spp. as the first and second most predominant agent of dysentery and mod...
| Автори: | , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Формат: | Journal article |
| Мова: | English |
| Опубліковано: |
eLife Sciences Publications
2022
|
| _version_ | 1826307675334377472 |
|---|---|
| author | Fernández Alvaro, E Voong Vinh, P de Cozar, C Willé, D Urones, B Cortés, A Price, A Tran Do Hoang, N Ha Thanh, T McCloskey, M Shaheen, S Dayao, D de Mercado, J Castañeda, P García-Perez, A Singa, B Pavlinac, P Walson, J Martínez-Martínez, MS Arnold, SLM Saul, T Ballell, L Baker, S |
| author_facet | Fernández Alvaro, E Voong Vinh, P de Cozar, C Willé, D Urones, B Cortés, A Price, A Tran Do Hoang, N Ha Thanh, T McCloskey, M Shaheen, S Dayao, D de Mercado, J Castañeda, P García-Perez, A Singa, B Pavlinac, P Walson, J Martínez-Martínez, MS Arnold, SLM Saul, T Ballell, L Baker, S |
| author_sort | Fernández Alvaro, E |
| collection | OXFORD |
| description | <strong>Background:<br></strong>
Diarrhoea remains one of the leading causes of childhood mortality globally. Recent epidemiological studies conducted in low-middle income countries (LMICs) identified Shigella spp. as the first and second most predominant agent of dysentery and moderate diarrhoea, respectively. Antimicrobial therapy is often necessary for Shigella infections; however, we are reaching a crisis point with efficacious antimicrobials. The rapid emergence of resistance against existing antimicrobials in Shigella spp. poses a serious global health problem.
<br><strong>
Methods:<br></strong>
Aiming to identify alternative antimicrobial chemicals with activity against antimicrobial resistant Shigella, we initiated a collaborative academia-industry drug discovery project, applying high-throughput phenotypic screening across broad chemical diversity and followed a lead compound through in vitro and in vivo characterisation.
<br><strong>
Results:<br></strong>
We identified several known antimicrobial compound classes with antibacterial activity against Shigella. These compounds included the oral carbapenem Tebipenem, which was found to be highly potent against broadly susceptible Shigella and contemporary MDR variants for which we perform detailed pre-clinical testing. Additional in vitro screening demonstrated that Tebipenem had activity against a wide range of other non-Shigella enteric bacteria. Cognisant of the risk for the development of resistance against monotherapy, we identified synergistic behaviour of two different drug combinations incorporating Tebipenem. We found the orally bioavailable prodrug (Tebipenem pivoxil) had ideal pharmacokinetic properties for treating enteric pathogens and was effective in clearing the gut of infecting organisms when administered to Shigella-infected mice and gnotobiotic piglets.
<br><strong>
Conclusions:<br></strong>
Our data highlight the emerging antimicrobial resistance crisis and shows that Tebipenem pivoxil (licenced for paediatric respiratory tract infections in Japan) should be accelerated into human trials and could be repurposed as an effective treatment for severe diarrhoea caused by MDR Shigella and other enteric pathogens in LMICs.
<br><strong>
Funding:<br></strong>
Tres Cantos Open Lab Foundation (projects TC239 and TC246), the Bill and Melinda Gates Foundation (grant OPP1172483) and Wellcome (215515/Z/19/Z). |
| first_indexed | 2024-03-07T07:06:42Z |
| format | Journal article |
| id | oxford-uuid:c299c9c6-cba1-4669-ae3d-d2b956b57c0c |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T07:06:42Z |
| publishDate | 2022 |
| publisher | eLife Sciences Publications |
| record_format | dspace |
| spelling | oxford-uuid:c299c9c6-cba1-4669-ae3d-d2b956b57c0c2022-05-04T12:55:54ZThe repurposing of Tebipenem pivoxil as alternative therapy for severe gastrointestinal infections caused by extensively drug-resistant Shigella sppJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:c299c9c6-cba1-4669-ae3d-d2b956b57c0cEnglishSymplectic ElementseLife Sciences Publications2022Fernández Alvaro, EVoong Vinh, Pde Cozar, CWillé, DUrones, BCortés, APrice, ATran Do Hoang, NHa Thanh, TMcCloskey, MShaheen, SDayao, Dde Mercado, JCastañeda, PGarcía-Perez, ASinga, BPavlinac, PWalson, JMartínez-Martínez, MSArnold, SLMSaul, TBallell, LBaker, S<strong>Background:<br></strong> Diarrhoea remains one of the leading causes of childhood mortality globally. Recent epidemiological studies conducted in low-middle income countries (LMICs) identified Shigella spp. as the first and second most predominant agent of dysentery and moderate diarrhoea, respectively. Antimicrobial therapy is often necessary for Shigella infections; however, we are reaching a crisis point with efficacious antimicrobials. The rapid emergence of resistance against existing antimicrobials in Shigella spp. poses a serious global health problem. <br><strong> Methods:<br></strong> Aiming to identify alternative antimicrobial chemicals with activity against antimicrobial resistant Shigella, we initiated a collaborative academia-industry drug discovery project, applying high-throughput phenotypic screening across broad chemical diversity and followed a lead compound through in vitro and in vivo characterisation. <br><strong> Results:<br></strong> We identified several known antimicrobial compound classes with antibacterial activity against Shigella. These compounds included the oral carbapenem Tebipenem, which was found to be highly potent against broadly susceptible Shigella and contemporary MDR variants for which we perform detailed pre-clinical testing. Additional in vitro screening demonstrated that Tebipenem had activity against a wide range of other non-Shigella enteric bacteria. Cognisant of the risk for the development of resistance against monotherapy, we identified synergistic behaviour of two different drug combinations incorporating Tebipenem. We found the orally bioavailable prodrug (Tebipenem pivoxil) had ideal pharmacokinetic properties for treating enteric pathogens and was effective in clearing the gut of infecting organisms when administered to Shigella-infected mice and gnotobiotic piglets. <br><strong> Conclusions:<br></strong> Our data highlight the emerging antimicrobial resistance crisis and shows that Tebipenem pivoxil (licenced for paediatric respiratory tract infections in Japan) should be accelerated into human trials and could be repurposed as an effective treatment for severe diarrhoea caused by MDR Shigella and other enteric pathogens in LMICs. <br><strong> Funding:<br></strong> Tres Cantos Open Lab Foundation (projects TC239 and TC246), the Bill and Melinda Gates Foundation (grant OPP1172483) and Wellcome (215515/Z/19/Z). |
| spellingShingle | Fernández Alvaro, E Voong Vinh, P de Cozar, C Willé, D Urones, B Cortés, A Price, A Tran Do Hoang, N Ha Thanh, T McCloskey, M Shaheen, S Dayao, D de Mercado, J Castañeda, P García-Perez, A Singa, B Pavlinac, P Walson, J Martínez-Martínez, MS Arnold, SLM Saul, T Ballell, L Baker, S The repurposing of Tebipenem pivoxil as alternative therapy for severe gastrointestinal infections caused by extensively drug-resistant Shigella spp |
| title | The repurposing of Tebipenem pivoxil as alternative therapy for severe gastrointestinal infections caused by extensively drug-resistant Shigella spp |
| title_full | The repurposing of Tebipenem pivoxil as alternative therapy for severe gastrointestinal infections caused by extensively drug-resistant Shigella spp |
| title_fullStr | The repurposing of Tebipenem pivoxil as alternative therapy for severe gastrointestinal infections caused by extensively drug-resistant Shigella spp |
| title_full_unstemmed | The repurposing of Tebipenem pivoxil as alternative therapy for severe gastrointestinal infections caused by extensively drug-resistant Shigella spp |
| title_short | The repurposing of Tebipenem pivoxil as alternative therapy for severe gastrointestinal infections caused by extensively drug-resistant Shigella spp |
| title_sort | repurposing of tebipenem pivoxil as alternative therapy for severe gastrointestinal infections caused by extensively drug resistant shigella spp |
| work_keys_str_mv | AT fernandezalvaroe therepurposingoftebipenempivoxilasalternativetherapyforseveregastrointestinalinfectionscausedbyextensivelydrugresistantshigellaspp AT voongvinhp therepurposingoftebipenempivoxilasalternativetherapyforseveregastrointestinalinfectionscausedbyextensivelydrugresistantshigellaspp AT decozarc therepurposingoftebipenempivoxilasalternativetherapyforseveregastrointestinalinfectionscausedbyextensivelydrugresistantshigellaspp AT willed therepurposingoftebipenempivoxilasalternativetherapyforseveregastrointestinalinfectionscausedbyextensivelydrugresistantshigellaspp AT uronesb therepurposingoftebipenempivoxilasalternativetherapyforseveregastrointestinalinfectionscausedbyextensivelydrugresistantshigellaspp AT cortesa therepurposingoftebipenempivoxilasalternativetherapyforseveregastrointestinalinfectionscausedbyextensivelydrugresistantshigellaspp AT pricea therepurposingoftebipenempivoxilasalternativetherapyforseveregastrointestinalinfectionscausedbyextensivelydrugresistantshigellaspp AT trandohoangn therepurposingoftebipenempivoxilasalternativetherapyforseveregastrointestinalinfectionscausedbyextensivelydrugresistantshigellaspp AT hathanht therepurposingoftebipenempivoxilasalternativetherapyforseveregastrointestinalinfectionscausedbyextensivelydrugresistantshigellaspp AT mccloskeym therepurposingoftebipenempivoxilasalternativetherapyforseveregastrointestinalinfectionscausedbyextensivelydrugresistantshigellaspp AT shaheens therepurposingoftebipenempivoxilasalternativetherapyforseveregastrointestinalinfectionscausedbyextensivelydrugresistantshigellaspp AT dayaod therepurposingoftebipenempivoxilasalternativetherapyforseveregastrointestinalinfectionscausedbyextensivelydrugresistantshigellaspp AT demercadoj therepurposingoftebipenempivoxilasalternativetherapyforseveregastrointestinalinfectionscausedbyextensivelydrugresistantshigellaspp AT castanedap therepurposingoftebipenempivoxilasalternativetherapyforseveregastrointestinalinfectionscausedbyextensivelydrugresistantshigellaspp AT garciapereza therepurposingoftebipenempivoxilasalternativetherapyforseveregastrointestinalinfectionscausedbyextensivelydrugresistantshigellaspp AT singab therepurposingoftebipenempivoxilasalternativetherapyforseveregastrointestinalinfectionscausedbyextensivelydrugresistantshigellaspp AT pavlinacp therepurposingoftebipenempivoxilasalternativetherapyforseveregastrointestinalinfectionscausedbyextensivelydrugresistantshigellaspp AT walsonj therepurposingoftebipenempivoxilasalternativetherapyforseveregastrointestinalinfectionscausedbyextensivelydrugresistantshigellaspp AT martinezmartinezms therepurposingoftebipenempivoxilasalternativetherapyforseveregastrointestinalinfectionscausedbyextensivelydrugresistantshigellaspp AT arnoldslm therepurposingoftebipenempivoxilasalternativetherapyforseveregastrointestinalinfectionscausedbyextensivelydrugresistantshigellaspp AT sault therepurposingoftebipenempivoxilasalternativetherapyforseveregastrointestinalinfectionscausedbyextensivelydrugresistantshigellaspp AT ballelll therepurposingoftebipenempivoxilasalternativetherapyforseveregastrointestinalinfectionscausedbyextensivelydrugresistantshigellaspp AT bakers therepurposingoftebipenempivoxilasalternativetherapyforseveregastrointestinalinfectionscausedbyextensivelydrugresistantshigellaspp AT fernandezalvaroe repurposingoftebipenempivoxilasalternativetherapyforseveregastrointestinalinfectionscausedbyextensivelydrugresistantshigellaspp AT voongvinhp repurposingoftebipenempivoxilasalternativetherapyforseveregastrointestinalinfectionscausedbyextensivelydrugresistantshigellaspp AT decozarc repurposingoftebipenempivoxilasalternativetherapyforseveregastrointestinalinfectionscausedbyextensivelydrugresistantshigellaspp AT willed repurposingoftebipenempivoxilasalternativetherapyforseveregastrointestinalinfectionscausedbyextensivelydrugresistantshigellaspp AT uronesb repurposingoftebipenempivoxilasalternativetherapyforseveregastrointestinalinfectionscausedbyextensivelydrugresistantshigellaspp AT cortesa repurposingoftebipenempivoxilasalternativetherapyforseveregastrointestinalinfectionscausedbyextensivelydrugresistantshigellaspp AT pricea repurposingoftebipenempivoxilasalternativetherapyforseveregastrointestinalinfectionscausedbyextensivelydrugresistantshigellaspp AT trandohoangn repurposingoftebipenempivoxilasalternativetherapyforseveregastrointestinalinfectionscausedbyextensivelydrugresistantshigellaspp AT hathanht repurposingoftebipenempivoxilasalternativetherapyforseveregastrointestinalinfectionscausedbyextensivelydrugresistantshigellaspp AT mccloskeym repurposingoftebipenempivoxilasalternativetherapyforseveregastrointestinalinfectionscausedbyextensivelydrugresistantshigellaspp AT shaheens repurposingoftebipenempivoxilasalternativetherapyforseveregastrointestinalinfectionscausedbyextensivelydrugresistantshigellaspp AT dayaod repurposingoftebipenempivoxilasalternativetherapyforseveregastrointestinalinfectionscausedbyextensivelydrugresistantshigellaspp AT demercadoj repurposingoftebipenempivoxilasalternativetherapyforseveregastrointestinalinfectionscausedbyextensivelydrugresistantshigellaspp AT castanedap repurposingoftebipenempivoxilasalternativetherapyforseveregastrointestinalinfectionscausedbyextensivelydrugresistantshigellaspp AT garciapereza repurposingoftebipenempivoxilasalternativetherapyforseveregastrointestinalinfectionscausedbyextensivelydrugresistantshigellaspp AT singab repurposingoftebipenempivoxilasalternativetherapyforseveregastrointestinalinfectionscausedbyextensivelydrugresistantshigellaspp AT pavlinacp repurposingoftebipenempivoxilasalternativetherapyforseveregastrointestinalinfectionscausedbyextensivelydrugresistantshigellaspp AT walsonj repurposingoftebipenempivoxilasalternativetherapyforseveregastrointestinalinfectionscausedbyextensivelydrugresistantshigellaspp AT martinezmartinezms repurposingoftebipenempivoxilasalternativetherapyforseveregastrointestinalinfectionscausedbyextensivelydrugresistantshigellaspp AT arnoldslm repurposingoftebipenempivoxilasalternativetherapyforseveregastrointestinalinfectionscausedbyextensivelydrugresistantshigellaspp AT sault repurposingoftebipenempivoxilasalternativetherapyforseveregastrointestinalinfectionscausedbyextensivelydrugresistantshigellaspp AT ballelll repurposingoftebipenempivoxilasalternativetherapyforseveregastrointestinalinfectionscausedbyextensivelydrugresistantshigellaspp AT bakers repurposingoftebipenempivoxilasalternativetherapyforseveregastrointestinalinfectionscausedbyextensivelydrugresistantshigellaspp |